Januvia

Januvia

sitagliptin

Manufacturer:

Merck Sharp & Dohme
Concise Prescribing Info
Contents
Sitagliptin
Indications/Uses
As adjunct to diet & exercise to improve glycemic control in patients w/ type 2 DM. In combination w/ metformin or thiazolidinediones for the treatment of patients w/ type 2 DM inadequately controlled by a single agent alone, diet & exercise.
Dosage/Direction for Use
100 mg once daily. Moderate renal insufficiency (CrCl ≥30-<50 mL/min) 50 mg once daily. Severe renal insufficiency (CrCl <30 mL/min) 25 mg once daily.
Administration
May be taken with or without food.
Special Precautions
Type 1 DM or diabetic ketoacidosis, moderate or severe renal insufficiency; patients w/ end-stage renal disease requiring hemo- or peritoneal dialysis. Pregnancy & lactation. Ped patients.
Adverse Reactions
Abdominal pain, nausea, diarrhea; hypersensitivity reactions.
MIMS Class
ATC Classification
A10BH01 - sitagliptin ; Belongs to the class of dipeptidyl peptidase 4 (DPP-4) inhibitors. Used in the treatment of diabetes.
Presentation/Packing
Form
Januvia tab 100 mg
Packing/Price
2 × 14's (Rp281,960/boks)
Form
Januvia tab 50 mg
Packing/Price
2 × 14's (Rp281,960/boks)
Form
Januvia tab 25 mg
Packing/Price
2 × 14's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in